-
Developing a new home monitoring device for dyskinesia in Parkinson’s disease
-
Developing palliative care clinics for patients with advanced Parkinson’s disease: Practical approaches, challenges, and experiences
-
Development and external validation of a prognostic model of mortality in Parkinson’s disease
-
Development of a human neuroblastoma model of pantothenate kinase-associated neurodegeneration
-
Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model
-
Development of a nanoherbaceutical formulation containing compound extracts from huperzia serrata, mucuna pruriens and withania somnifera for the prevention and treatment of Parkinson’s disease
-
Development of a tool for assessment of embarrassment due to dystonia
-
Development of hyperkinesias after long term pallidal stimulation for dystonia
-
Development of the UK hereditary spastic paraplegia registry: Analysis of SPAST patients reveals high rate of psychiatric comorbidities
-
Developmental movement patterns resemble movement disorder features in healthy babies and toddlers
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 207
- Next Page »